Journal Article

Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine

Reis, Laise Rodrigues, Martins-Filho, Olindo Assis, Souza-Lopes, Thalles, Albuquerque, Elizabeth Maciel de, Coelho-dos-Reis, Jordana Grazziela, Domingues, Carla Magda, Costa-Rocha, Ismael Artur da, Peruhype-Magalhães, Vanessa, Homma, Akira, Camacho, Luiz Antonio Bastos, Mambrini, Juliana Vaz de Melo, Martins, Reinaldo de Menezes, Farias, Roberto Henrique Guedes, Fradico, Jordana Rodrigues Barbosa, Freire, Larissa Chaves, Teixeira-Carvalho, Andréa, Campi-Azevedo, Ana Carolina, Castro, Thalita da Matta de, Lima, Sheila Maria Barbosa de, Xavier, Janaina Reis, Romano, Alessandro Pecego Martins, Maia, Maria de Lourdes de Sousa, Noronha, Tatiana Guimarães de, Costa-Pereira, Christiane

2019

Overview

The present study aims to determine whether 17DD-YF-specific humoral and cellular immunological memory is maintained 8-years after primary vaccination with subdoses (10,447IU;3,013IU;587IU;158IU;31IU). For this purpose, this follow-up study was carried out in a subset of volunteers ( = 98) originally enrolled in the dose-response study in 2009 and 46 non-vaccinated controls. Our results demonstrated that vaccinees, who had seroconverted following primary vaccination and had not been revaccinated, present similar neutralizing antibodies levels and YF-specific cellular memory, particularly CMCD4 and EMCD8 as compared to the reference full dose (27,476IU). Although, PRNT seropositivity rates were similar across subgroups (94, 82, 83, 94, 80, and 91%, correspondingly), only doses above 587IU elicited similar iterative proportion of seropositivity rates, calculated as a progressive decrease on seropositivity rates along time (89, 80, 80, and 91%, respectively) as compared to 158IU and 31IU (68 and 46%, respectively). Noteworthy were the strong positive correlations (\"EMCD4,EMCD8\" and \"TNFCD8,IFNCD8\") observed in most subdoses, except for 31IU. Major similarities underscored the preserved antibody titers and the outstanding levels of EMCD8, relevant correlates of protection for YF-specific immunity. These findings provide evidences to support the regular use of dose sparing strategy for YF vaccine in adults.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: 17DD vaccine / Adult / Antibodies / Antibodies, Neutralizing - blood / Anticoagulants / Cell-mediated immunity / cellular memory / Clinical trials / Collaboration / Dose-Response Relationship, Drug / Double-Blind Method / Fever / Follow-Up Studies / Humans / Humoral immunity / Immunologic Memory - immunology / Immunological memory / Immunology / Male / neutralizing antibodies / subdoses / Vaccines / Yellow Fever / Yellow Fever - prevention & control / Yellow Fever Vaccine - administration & dosage / Yellow Fever Vaccine - immunology